Sangamo enters into asset sale agreements with Lilly and Astellas

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Poster: ST-503 nonclinical safety studies evaluating zinc finger repressors regulating expression of the Nav1.7 gene for treatment of small fiber neuropathy

Download PDF